Challenges in defining, diagnosing, and treating diabetic gastroparesis

Molecular Mechanisms of Hawthorn Extracts in Multiple Organs Disorders in Underlying of Diabetes: A Review

Diabetes mellitus (DM) is one of the most important metabolic disorders associated with chronic hyperglycemia and occurs when the body cannot manage insulin secretion, insulin action, or both. Autoimmune destruction of pancreatic beta cells and insulin resistance are the major pathophysiological factors of types 1 and 2 of DM, respectively. Prolonged hyperglycemia leads to multiple organs dysfunctions, including nephropathy, neuropathy, cardiomyopathy, gastropathy, and micro- and macrovascular disorders. The basis of the metabolic abnormalities in carbohydrate, fat, and protein in diabetes is insufficient action of insulin on various target tissues. Medicinal plants are rich sources of bioactive chemical compounds with therapeutic effects. The beneficial effects of leaves, fruits, and flowers extracts of Crataegus oxyacantha, commonly called hawthorn, belonging to the Rosaceae family, are widely used as hawthorn-derived medicines. Data in this review have been collected from the scientific articles published in databases such as Science Direct, Scopus, PubMed, Web of Science, and Scientific Information Database from 2000 to 2021. Based on this review, hawthorn extracts appear both therapeutic and protective effects against diabetic-related complications in various organs through molecular mechanisms, such as decreasing triglyceride, cholesterol, very low density lipoprotein and increasing the antioxidant activity of superoxide dismutase, catalase, glutathione peroxidase, total antioxidant capacity, decreasing malondialdehyde level, and attenuating tumor necrosis factor alpha, interleukin 6 and sirtuin 1/AMP-activated protein kinase (AMPK)/nuclear factor kappa B (NF-κB) pathway and increasing the phosphorylation of glucose transporter 4, insulin receptor substrate 1, AKT and phosphoinositide 3-kinases, and attenuating blood sugar and regulation of insulin secretion, insulin resistance, and improvement of histopathological changes in pancreatic beta cells. Collectively, hawthorn can be considered as one new target for the research and development of innovative drugs for the prevention or treatment of DM and related problems.

The efficacy and safety of Tuina for diabetic gastroparesis: A protocol for systematic review and meta-analysis

BACKGROUND

Diabetic gastroparesis (DGP) is one of the most common complication of diabetes. At present, despite the increasing number of clinical researches of treatment with Tuina have been reported, there are no systematic reviews of Tuina therapy for DGP. Therefore, it is of great significance to evaluate its safety and efficacy as a complementary and alternative therapy.

METHODS AND ANALYSIS

Randomized controlled trials (RCTs) of Tuina therapy in the treatment of DGP will be retrieved from PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang Database (Wan Fang), Chinese Biomedical Literature Database (CBM), VIP Database for Chinese Technical Periodicals (VIP), Medline, and Clinical Trial Register (CTR). We will consider articles published in English or Chinese between database initiation and October 2021. Research selection, data extraction, risk of bias assessment, and meta-analyses will be independently completed by 2 researchers. Our researchers will use Revman 5.3 software, provided by the Cochrane Collaborative Network for conducting systematic reviews and meta-analysis.

RESULTS

This systematic review provides a high-quality synthesis to assess the effectiveness and safety of Tuina therapy for treating DGP.

CONCLUSION

The conclusions of our study will provide evidence to determine whether Tuina therapy is an effective and safe intervention for patients with DGP.

SYSTEMATIC REVIEW REGISTRATION

: INPLASY2021110019.

A computational model of radiofrequency ablation in the stomach, an emerging therapy for gastric dysrhythmias

Gastric ablation has recently emerged as a promising potential therapy for bioelectrical dysrhythmias that underpin many gastrointestinal disorders. Despite similarities to well-developed cardiac ablation, gastric ablation is in early development and has thus far been limited to temperature-controlled, non-irrigated settings. A computational model of gastric ablation is needed to enable in silico testing and optimization of ablation parameters and techniques. In this study, we developed a computational model of radio-frequency (RF) gastric ablation. Model parameters and boundary conditions were established based on the current in vivo experimental application of serosal gastric ablation with a non-irrigated RF catheter. The Pennes bioheat transfer equation was used to model the thermal component of RF ablation, and Laplace's equation was used to model the Joule heating component. Tissue, blood, and catheter parameters were obtained from literature. The performance of the model was compared to previously established experimental values of temperature measured from various distances from the catheter tip. The model produced temperature estimations that were within 6% of the maximum experimental temperature at 2.5 mm from the catheter, and within 13% of the maximum temperature change at 4.7 mm. This model now provides a computational basis through which to conduct in silico testing of gastric ablation, and can be usefully applied to optimize gastric ablation parameters. In future, the model can be expanded to include irrigation of the catheter tip and power-controlled RF settings.Clinical Relevance- This work presents a computational model of gastric ablation that can now guide the in silico development of effective ablation parameters and therapeutic strategies, expanding the breadth of this promising therapy.

Electroacupuncture at ST36 Improve the Gastric Motility by Affecting Neurotransmitters in the Enteric Nervous System in Type 2 Diabetic Rats

Electroacupuncture (EA) can effectively relieve hyperglycemia and gastric emptying disorders in diabetic gastroparesis (DGP). However, the effect of EA on type 2 diabetes mellitus (T2DM) gastroparesis and its mechanism in the enteric nervous system (ENS) are rarely studied. We investigated the therapeutic effect of EA at ST36 and its effect on the main inhibitory and excitatory neurotransmitters in the ENS in DGP rats. Male Sprague-Dawley (SD) rats were fed a high-fat diet for 2 weeks and injected with streptozotocin (STZ) at 35 mg/kg to induce T2DM. T2DM rats were divided into the diabetic mellitus (DM) group and the EA group. The control (CON) group comprised normal rats without any intervention. EA treatment was started 6 weeks after the induction of DM and continued for 5 weeks. The body weight and food intake of the rats were recorded every week. Blood glucose, insulin, glucose tolerance, gastric emptying, and antral motility were measured after treatment. The expression of protein gene product 9.5 (PGP9.5), neuronal nitric oxide synthase (nNOS), and choline acetyltransferase (ChAT) in gastric antrum were quantified by western blotting and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The T2DM gastroparesis model was successfully established. EA treatment reduced the body weight, food intake, and blood glucose; improved glucose intolerance and insulin resistance; increased the gastric emptying rate, the mean antral pressure, and the amplitude of antral motility; and decreased the frequency of antral motility compared with those in the DM group. EA treatment increased the expression level of nNOS, ChAT, and PGP9.5 proteins, and nNOS and ChAT mRNA. The results suggested that EA at ST36 could ameliorate DGP, partly restore the damage to general neurons, and increase nNOS and ChAT in the gastric antrum. EA improved DGP partly via reducing the loss of inhibitory and excitatory neurotransmitters in the ENS.

Gastric ablation as a novel technique for modulating electrical conduction in the in vivo stomach

Gastric motility is coordinated by underlying bioelectrical "slow wave" activity. Slow wave dysrhythmias are associated with motility disorders, including gastroparesis, offering an underexplored potential therapeutic target. Although ablation is widely used to treat cardiac arrhythmias, this approach has not yet been trialed for gastric electrical abnormalities. We hypothesized that ablation can create localized conduction blocks and modulate slow wave activation. Radiofrequency ablation was performed on the porcine serosa in vivo, encompassing a range of parameters (55-85°C, adjacent points forming a line, 5-10 s/point). High-resolution electrical mapping (16 × 16 electrodes; 6 × 6 cm) was applied to define baseline and acute postablation activation patterns. Tissue damage was evaluated by hematoxylin and eosin and c-Kit stains. Results demonstrated that RF ablation successfully induced complete conduction block and a full thickness lesion in the muscle layer at energy doses of 65-75°C for 5-10 s/point. Gastric ablation may hold therapeutic potential for gastric electrical abnormalities in the future.NEW & NOTEWORTHY This study presents gastric ablation as a new method for modulating slow wave activation and propagation in vivo, by creating localized electrical conduction blocks in the stomach, validated by high-resolution electrical mapping and histological tissue analysis. The results define the effective energy dose range for creating conduction blocks, while maintaining the mucosal and submucosal integrity, and demonstrate the electrophysiological effects of ablation. In future, gastric ablation can now be translated toward disrupting dysrhythmic slow wave activation.

Transmural Temperature Monitoring to Quantify Thermal Conduction And Lesion Formation During Gastric Ablation, an Emerging Therapy for Gastric Dysrhythmias

Gastric ablation is emerging as a potential therapy for electrical dysrhythmias associated with gastric disorders. Thermal conduction properties of gastric tissue during ablation have not yet been defined, but are necessary for optimizing the technique and translating ablation to clinical therapy. We developed custom needle-based transmural temperature probes to quantify the temperature of gastric tissue during ablation. These probes were applied in vivo in pigs (n=5), during gastric ablation (70 °C, 10 s duration), at distances of 2.5 - 20 mm from the ablation catheter tip. Thermal response of the tissue was non-linear; the maximum temperature increase from baseline (33.3 ± 1.0 °C) was observed at the closest temperature probe to the catheter tip (2.5 mm, 14.9 °C), and temperature change decreased with distance from the catheter tip. Probes positioned between 5 -20 mm from the catheter tip recorded temperature increases of less than 5.6 °C. This study provides methods for monitoring temperature during in vivo ablation, and demonstrates that functional temperature increases from ablation were restricted to within approximately 5 mm of the catheter. These methods can now be applied to optimize effective ablation parameters, and to inform models of gastric ablation.

Feasibility of High-Resolution Electrical Mapping for Characterizing Conduction Blocks Created by Gastric Ablation

The interstitial cells of Cajal (ICC) initiate, coordinate and propagate bioelectrical slow wave activity that drives gastric motility. In the healthy human stomach, slow wave activity is highly organized. Gastric motility disorders are associated with dysrhythmias. While ablation is widely used to treat cardiac dysrhythmias, this approach has yet to be trialed in the stomach. In this study, radiofrequency (RF) ablation was applied in pig stomachs in vivo to create targeted electrical conduction blocks. Ablations were performed at temperature control mode (55-70°C), and resultant conduction blocks were identified and verified using high-resolution electrical mapping. Termination of slow wave propagation at ablation sites was confirmed by a decrease in extracellular slow wave amplitude from 1.7 ± 0.2 mV to an undetectable amplitude, as well as spatiotemporal pattern analysis of conduction blocks. The use of high-resolution electrical mapping can now be employed to investigate ablation as a potential therapy for gastric dysrhythmias in motility disorders.

Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis

OBJECTIVES

Diabetic gastroparesis (Gp) occurs more often in type 1 diabetes mellitus (T1DM) than in type 2 diabetes mellitus (T2DM). Other diabetic end-organ complications include peripheral neuropathy, nephropathy, and retinopathy (together termed triopathy). This study determines the prevalence of diabetic complications (retinopathy, nephropathy, and peripheral neuropathy) in diabetic patients with symptoms of Gp, assessing the differences between T1DM and T2DM and delayed and normal gastric emptying (GE).

METHODS

Diabetic patients with symptoms of Gp underwent history and physical examination, GE scintigraphy, electrogastrography with water load, autonomic function testing, and questionnaires assessing symptoms and peripheral neuropathy.

RESULTS

One hundred thirty-three diabetic patients with symptoms of Gp were studied: 59 with T1DM and 74 with T2DM and 103 with delayed GE and 30 without delayed GE. The presence of retinopathy (37% vs 24%; P = 0.13), nephropathy (19% vs 11%; P = 0.22), and peripheral neuropathy (53% vs 39%; P = 0.16) was not significantly higher in T1DM than in T2DM; however, triopathies (all 3 complications together) were seen in 10% of T1DM and 3% of T2DM (P = 0.04). Diabetic patients with delayed GE had increased prevalence of retinopathy (36% vs 10%; P = 0.006) and number of diabetic complications (1.0 vs 0.5; P = 0.009); however, 39% of diabetic patients with delayed GE did not have any diabetic complications.

DISCUSSION

In diabetic patients with symptoms of Gp, delayed GE was associated with the presence of retinopathy and the total number of diabetic complications. Only 10% of patients with T1DM and 3% of those with T2DM had triopathy of complications, and 39% of diabetic patients with Gp did not have any diabetic complications. Thus, the presence of diabetic complications should raise awareness for Gp in either T1DM or T2DM; however, diabetic Gp frequently occurs without other diabetic complications.